Hyrnuo Sevabertinib Application Scope

Hyrnuo is indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring activating HER2 (ERBB2) mutations, who have received at least one prior systemic therapy.

Sevabertinib Characteristics

Ingredients: Each tablet contains sevabertinib as the active ingredient.
Properties: Film-coated tablets
Packaging Specification: 10 mg × 120 tablets per bottle
Storage: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F to 86°F). Keep tightly closed.
Expiry Date: Refer to the product label.
Executive Standard: In accordance with approved regulatory standards (NMPA-approved specifications).
Approval Number: Refer to the official approval document issued by the National Medical Products Administration (NMPA).
Date of Revision: Refer to the latest approved package insert.
Manufacturer: Bayer HealthCare Pharmaceuticals Inc.

Guidelines for the Use of Hyrnuo

Dosage and Administration:
- Recommended Dose: 20 mg orally once daily
- Administration: Administer orally, with or without food. Swallow the tablets whole with water, and continue treatment until disease progression or unacceptable toxicity occurs.
- Missed Dose: If a dose is missed, it should be taken as soon as possible on the same day. If it is close to the next scheduled dose, skip the missed dose. Do not take a double dose.
Adverse Reactions:
- Common Adverse Reactions: Common adverse reactions include diarrhea, rash, nausea, fatigue, and decreased appetite.
- Serious Adverse Reactions: Serious adverse reactions may include interstitial lung disease (ILD)/pneumonitis, severe diarrhea, hepatotoxicity, and potential QT interval prolongation.
Contraindications: Known hypersensitivity to sevabertinib or any component of the formulation.
Precautions:
- Monitor for pulmonary symptoms (risk of ILD/pneumonitis)
- Monitor liver function during treatment
- Use caution in patients with cardiac risk factors
- Avoid use during pregnancy and breastfeeding

Sevabertinib Interactions

May interact with strong CYP3A4 inhibitors or inducers
Avoid concomitant use with drugs affecting QT interval

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.